What Viz.ai Reported About Reaching 2,000 Hospitals
Viz.ai published a ten year milestone announcement on July 28, 2026 stating that it operates in 2,000 hospitals, covers 230 million patients and holds 13 FDA clearances. The company says it received the first FDA De Novo authorizations for AI computer aided triage software and for ECG-based cardiovascular management software, and that it was the first company to receive Medicare reimbursement for AI software through the New Technology Add-on Payment program. All of these figures and firsts are the company's own account. The announcement does not break the 13 clearances down into individual submissions.
Why Viz.ai Scale and Reimbursement Matter to Stroke Programs
For time-critical conditions, installed base is close to the whole product, because an algorithm that is not running at the hospital a stroke patient reaches does nothing. Two notes on the wording: a De Novo is granted or authorized rather than cleared, and the two terms are not interchangeable even when a company uses them loosely. The reimbursement claim is the more durable one, because being first through Medicare's add-on payment program left behind a route other imaging AI companies now follow.
Where the Viz.ai Update Comes From
Viz.ai is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
How We Would Research the Viz.ai Hospital and Clearance Numbers
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would start by matching the 13 clearances to real submission numbers in the FDA database, since a count without numbers cannot be checked.
- Then we would separate hospitals running the full Viz platform from hospitals running a single module.
- We would ask what 230 million patients covered means, because a catchment population is not a count of patients whose scans were analyzed.